ZIMBABWE is currently experiencing a shortage in Rifabutin 150 mg tablets used in the treatment of drug sensitive Tuberculosis (DS-TB) among TB/HIV co-infected patients on second line treatment antiretroviral therapy (ART).
By Michael Gwarisa
In a communique written to all provincial hospitals, Permanent Secretary in the ministry of health and child care (MoHCC), Dr Jasper Chimedza said based on the current stock levels, the country would be stocked out by end of November 2020.
The country is currently faced with shortages of Rifubutin 150mg tablets. The shortages are associated with active pharmaceutical ingredient quality issues at the manufacturer level.
The next shipment delivery is expected in mid-2021. Based on the current stock levels of the commodity, the country will be stocked out by the end of November 2020,” said Dr Chimedza.
He further directed all clinicians to stop initiating new patients in Rifabutin based regimen.
“Clinicians are recommended to do the following, initiate the patients on Rifampicin based regimen (2RHZE/2RH). Substitute Atnazanavir/Ritonavir (ATV/r) with Lopinavir/Ritonavir (LPV/r), and either give LPV /r twice daily (double the dose) or increase Ritonavir to 400 mg (super bosting).
“Monitor closely for potential adverse events for due to the h8gh dose. Kindly liaise with the district pharmacist and or the NATPHARM logistics unit to ensure you have adequate supplies of LPV/r.)